CNBX Pharmaceuticals focuses on developing innovative therapies for various medical conditions, particularly in the field of cannabinoid-based treatments. The company is dedicated to advancing its proprietary technologies that leverage the therapeutic potential of cannabinoids. Their research emphasizes the development of formulations that enhance the bioavailability and efficacy of cannabinoids, aiming to provide safer and more effective treatment options for patients.

The company’s pipeline includes a range of products that target specific health issues, utilizing their advanced delivery systems to optimize the therapeutic effects of cannabinoids. CNBX Pharmaceuticals is committed to rigorous scientific research and clinical trials to validate the safety and effectiveness of their products. By integrating cutting-edge scientific methodologies with a focus on patient needs, CNBX aims to lead the way in cannabinoid-based medicine, addressing unmet medical needs and improving patient outcomes.

United States

CNBX Pharmaceuticals is a publicly traded company (CNBX: OTCQB) and developer of the world's first cannabinoid-based antitumor drug candidate for the treatment of colorectal cancer based on the company's novel and proprietary formulation CNBX™️ RCC-33.

CNBX Pharmaceuticals

Company Details